One year after the US FDA granted approval to the first “follow-on” insulin, the long-acting insulin glargine product has been officially launched in the United States. Approved as a follow-on and not a biosimilar, the long-acting insulin glargine has already been made available in Europe, and is available as a 100 Units/mL strength in 3-mL prefilled pens. It can be used in both children and adults with type 1 diabetes and adults with type 2 diabetes.

References:

Basaglar now available for type 1, type 2 diabetes.

FDA approves Basaglar, the first “follow-on” insulin glargine product to treat diabetes.

Share onShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn